By Scott Gottlieb (original source Health Affairs)
“In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of new medical technologies. Enhanced funding through user fees and the bipartisan Twenty-First Century Cures legislation have supported a robust and better-resourced FDA and enabled science-driven collaborations in a range of areas including innovative clinical trials, “patient-focused” drug development, and greater clarity around standards for regulatory approval of new technologies.”
Click here to read more
Patrick McGee: “Apple in China: The Capture of the World’s Greatest Company” | The Daily Show
Award-winning journalist Patrick McGee joins Jon Stewart to discuss how Apple built China in his new book “Apple in China: The Capture of the World’s…
Thought Leader: Patrick McGee
Peter Zeihan: The Fire Hose of Chaos: The “Deal” With the Chinese
Trade tensions are taking their toll on an already fragile Chinese system. The US is dealing with self-sufficiency problems, but for China, it is an…
Thought Leader: Peter Zeihan
Apple’s Chinafication with Patrick McGee | American Compass Podcast
The company’s corporate story is really about China, and how it came to dominate global industry. The Trump administration’s new trade policy toward China has…
Thought Leader: Patrick McGee
